Capreomycin

CHEMBL2221250 Phase 4 Approved Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1321.4 g/mol

LogP

—

Phase

4

A cyclic peptide antibiotic used to treat multidrug-resistant tuberculosis, particularly when first-line drugs have failed or cannot be used. It works by inhibiting bacterial protein synthesis at the ribosomal level. It must be given by injection and requires monitoring for kidney toxicity and hearing loss.

Molecular Weight

1321.4000 g/mol

TPSA

737.00 Å²

Therapeutic Areas

Tuberculosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H](C2CCNC(=N)N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC1=O.N=C1NCCC([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O)N1

InChI

InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9-;16-10-/t11?,12-,13?,14-,16-,18-;11-,12?,13-,14?,15-,18-/m00/s1

Molecular Formula

C50H88N28O15

HBD / HBA

27 / 23

Rotatable Bonds

19

Heavy Atoms

93

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A cyclic peptide antibiotic used to treat multidrug-resistant tuberculosis, particularly when first-line drugs have failed or cannot be used. It works by inhibiting bacterial protein synthesis at the ribosomal level. It must be given by injection and requires monitoring for kidney toxicity and hearing loss.

Yes, Capreomycin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2221250. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3000502. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Capreomycin on PillFYI

Structure

Quick Data

Formula: C50H88N28O15

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.